NASDAQ:KPRX • US49721T5074
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KIORA PHARMACEUTICALS INC (KPRX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-09 | Maxim Group | Maintains | Buy -> Buy |
| 2023-05-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-03-24 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-09 | Maxim Group | Upgrade | Hold -> Buy |
| 2023-02-08 | Ladenburg Thalmann | Reiterate | Buy |
| 2023-02-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-08-25 | Ladenburg Thalmann | Initiate | Buy |
| 2022-08-15 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-07-11 | HC Wainwright & Co. | Maintains | Buy |
| 2022-04-19 | HC Wainwright & Co. | Maintains | Buy |
| 2022-01-19 | Maxim Group | Initiate | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 16.02M | 1.53M -100.00% | 1.53M | -100.00% | 23.231M | 57.659M 148.20% | 171.13M 196.80% | 243.19M 42.11% | 306.5M 26.03% | |||
| EBITDA YoY % growth | -12.27M -20.89% | -10.631M 13.36% | 6.538M 161.50% | N/A -225.16% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -12.31M -20.69% | -10.683M 13.22% | 6.518M 161.02% | -8.545M -225.91% | -19.208M -134.04% | -27.336M -42.32% | -6.495M 76.24% | 21.832M 436.12% | 118.92M 444.71% | 182.36M 53.35% | 243.2M 33.36% | |
| Operating Margin | N/A | N/A | 40.69% | -558.47% | -1,255.40% | N/A | -27.96% | 37.86% | 69.49% | 74.99% | 79.35% | |
| EPS YoY % growth | -232.11 61.43% | -28.35 87.79% | 1.04 103.67% | -1.74 -353.85% | -2.39 9.59% | -1.79 25.21% | -0.41 77.14% | 5.65 1,485.00% | 16.49 191.88% | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.72 -39.27% | -0.69 -28.44% | -0.74 -7,546.00% | -0.78 51.25% | -0.59 18.31% | -0.61 11.76% | -0.51 31.51% | -0.53 31.58% |
| Revenue Q2Q % growth | 1.53M | N/A | N/A | N/A | N/A | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.121M -33.93% | -3.257M -35.92% | -3.528M -344.13% | -3.664M -36.40% | -4.393M -40.75% | -4.584M -40.75% | -6.84M -93.87% | -7.103M -93.88% |
All data in USD
7 analysts have analysed KPRX and the average price target is 12.24 USD. This implies a price increase of 420.85% is expected in the next year compared to the current price of 2.35.
KIORA PHARMACEUTICALS INC (KPRX) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of KIORA PHARMACEUTICALS INC (KPRX) is -0.72 USD and the consensus revenue estimate is 1.53M USD.
The consensus rating for KIORA PHARMACEUTICALS INC (KPRX) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.